Article thumbnail
Location of Repository

The use of bupropion SR in cigarette smoking cessation

By Scott Wilkes


Cigarette smoking remains the largest preventable cause of premature death in developed countries. Until recently nicotine replacement therapy (NRT) has been the only recognised form of treatment for smoking cessation. Bupropion, the first non-nicotine based drug for smoking cessation was licensed in the United States of America (US) in 1997 and in the United Kingdom (UK) in 2000 for smoking cessation in people aged 18 years and over. Bupropion exerts its effect primarily through the inhibition of dopamine reuptake into neuronal synaptic vesicles. It is also a weak noradrenalin reuptake inhibitor and has no effect on the serotonin system. Bupropion has proven efficacy for smoking cessation in a number of clinical trials, helping approximately one in five smokers to stop smoking. Up to a half of patients taking bupropion experience side effects, mainly insomnia and a dry mouth, which are closely linked to the nicotine withdrawal syndrome. Bupropion is rarely associated with seizures however care must be taken when co-prescribing with drugs that can lower seizure threshold. Also, bupropion is a potent enzyme inhibitor and can raise plasma levels of some drugs including antidepressants, antiarrhythmics and antipsychotics. Bupropion has been shown to be a safe and cost effective smoking cessation agent. Despite this, NRT remains the dominant pharmacotherapy to aid smoking cessation

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1997). A comparison of sustainedrelease bupropion and placebo for smoking cessation.
  2. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
  3. (2005). A double-blind placebocontrolled trial of bupropion sustained-release for smoking cessation in schizophrenia.
  4. (2004). A multicenter, randomised, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees.
  5. (2003). A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.
  6. (2005). Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin.
  7. (2005). Adverse effects associated with extra doses of bupropion.
  8. (2005). Adverse effects of pharmacological therapy for nicotine addiction in smokers following a smoking cessation program.
  9. (2005). An innovative tobacco use cessation program for military dental clinics.
  10. (2004). Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews,
  11. (2004). Are there gender differences in smoking cessation, with and without bupropion? Pooled and meta-analyses of clinical trials of Bupropion SR.
  12. (2005). Assisting smoking cessation. Revue des Maladies Respiratoires,
  13. (2005). Bupropion (amfebutamone): caution during pregnancy.
  14. (2005). Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clinical Therapeutics 27:1685–95.
  15. (2006). Bupropion for smoking cessation. A Review. Comprehensive Therapy,
  16. (2005). Bupropion increases striatal vesicular monoamine transport.
  17. (2002). Bupropion inhibits [(3)H] overfl ow from rat striatal slices preloaded with [(3)] dopamine and from rat hippocampal slices preloaded with [(3)] norepinephrine.
  18. (2000). Bupropion is a nicotinic antagonist.
  19. (2001). Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clinical Pharmacology and Therapeutics,
  20. (2003). Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.
  21. (2005). Bupropion SR vs placebo for smoking cessation in health care professionals.
  22. (2000). Bupropion to aid smoking cessation. Drug and Therapeutics Bulletin,
  23. (2005). Bupropion-induced subacute cutaneous lupus erythematosus.
  24. (1995). Bupropion: a review of its mechanism of antidepressant activity.
  25. (2005). Bupropion: risks and benefi ts. Expert Opinion on Drug Safety,
  26. (2005). Buproprion, public funding, and smoking cessation.
  27. (2000). College of Physicians of London.
  28. (2005). Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation.
  29. (2003). Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin.
  30. (2006). Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
  31. (1992). Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum.
  32. (2004). Effects of sustainedrelease bupropion among persons interested in reducing but not quitting smoking.
  33. (2006). Effi cacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
  34. (2005). Effi cacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease.
  35. (2004). Effi cacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
  36. (2006). Effi cacy of varenicline, an alpha2beta4 nicotinic acetylecholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized trial.
  37. (2003). Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in
  38. Exp Ther,
  39. (2006). Extended treatment with bupropion SR for cigarette smoking cessation.
  40. (2006). General practitioners’ beliefs about effectiveness and intentions to prescribe smoking cessation medications: qualitative and quantitative studies.
  41. (2007). health. Nurse independent prescribing. Accessed
  42. (2005). Health. Statistics on NHS Stop Smoking services in England,
  43. (2006). Hemodynamic effects of bupropion in anesthetized dogs.
  44. (2005). How does bupropion work as a smoking cessation aid? Addiction Biology,
  45. (2005). Inhibition of CYP2D6 activity by bupropion.
  46. (2002). Institute for Clinical Excellence.
  47. (2007). Institute for Health and Clinical Excellence.
  48. (2005). Intraventricular conduction delay after bupropion overdose.
  49. (2007). Maximizing smoking cessation in clinical practice: pharmacological and behavioural interventions. Preventive Cardiology,
  50. (2005). Non-nicotine pharmacotherapies for smoking cessation. Respiratory Medicine,
  51. (2006). Outcomes of bupropion therapy for smoking cessation during routine clinical use. Annals of Pharmacotherapy,
  52. (2006). Pharmacologic interventions for smoking cessation. Critical Care Nursing Clinics of North America,
  53. (2006). Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice.
  54. (2005). Pragmatic, observational study of bupropion treatment for smoking cessation in general practice.
  55. (2003). Review of bupropion for smoking cessation. Drug and Alcohol Review,
  56. (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
  57. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion.
  58. (1998). Secretary of State for Health.
  59. (2005). Self-effi cacy and motivation to quit during participation in a smoking cessation program.
  60. (2006). Six-month trial of bupropion with contingency management for cocaine dependence in a methadonemaintained population.
  61. (2006). Smoking cessation advice for patients with chronic periodontitis.
  62. (2006). Smoking cessation counselling and dental team. Annali di Igiene,
  63. (2000). Smoking cessation guidelines for health professionals:an update.
  64. (2001). Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebocontrolled, randomised trial.
  65. (2005). Smoking cessation in patients with coronary artery disease.
  66. (2007). Smoking cessation pharmacotherapy – nicotine and non-nicotine preparations. Preventive Cardiology,
  67. (2006). Social inequalities in male mortality, and in male mortality from smoking: indirect estimation from national death rates in
  68. (2002). Sustained-Release Bupropion for Smoking Cessation in African Americans.
  69. (2005). Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.
  70. (2002). The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technology Assessment
  71. (2006). The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
  72. (2005). The feasibility of smoking reduction: an update.
  73. (2005). The infl uence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion.
  74. (2005). The prevalence of weight concerns in a smoking abstinence clinical trial. Addictive Behaviours,
  75. (2005). Tobacco cessation for the dental team: a practical guide part II: evidence-based interventions.
  76. (2005). Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration.
  77. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
  78. (2006). Zyban (bupropion hydrochloride) Sustained Release Tablets. Product Information.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.